Recently, key molecules that regulate mucosal immunity and IBD pathogenesis, including those in the IL-33/ST2 signaling pathway, have emerged as suitable biomarkers in inflammatory conditions such as IBD [9, 10]. Here, IL1RL1 is linked to inflammatory bowel disease.